Your cart is currently empty!
Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in Canada
$1.00
All your purchased models will be available under your account under “Dashboards”
Disease Area (Primary)
Metastatic melanoma
First Developed
02/28/2019
Last Developed
05/27/2023
Software Used
R (e.g., heemod, BCEA, dampack, hesim)
Model Sponsor
Unknown
Intervention
dabrafenib
Model Validation Score
– %
Coming Soon In Phase II: You will be able to pay a fee to download the CADTH Tool for your model which includes subaggregated scores.
Results
Dabrafenib was estimated to yield 0.2055 more QALYs at higher cost than dacarbazine. The incremental cost-effectiveness ratio was CA$363,136/QALY. In probabilistic sensitivity analyses, at a threshold of CA$200,000/QALY, there was an 8.2 % probability that dabrafenib is cost effective versus dacarbazine.
Conclusion
At a threshold of CA$200,000/QALY, dabrafenib is unlikely to be cost effective compared with dacarbazine.
Source File(s)
Model:
Publication File:
Publication File 1:
Publication File 2:
Publication File 3:
Publication File 4:
No link submitted.
No link submitted.
No link submitted.
No link submitted.
Model Review
Only visible for the model owner
Summary
Validation Score
– %
Internal Comments
–
